Announcement • Jul 17
ME Therapeutics Holdings Inc. announced that it has received CAD 0.576501 million in funding On July 17, 2026, ME Therapeutics Holdings Inc. closed the oversubscribed transaction. The transaction consists of issuance of 339,118 units of the Company at an issue price of CAD 1.70 per Unit for gross proceeds of CAD 576,500.6. John Priatel, a director of the Company, acquired 294,118 Units pursuant to the financing for aggregate consideration of CAD 500,000.60 representing a price of CAD 1.70 per Unit. John Priatel also received 250,000 Options at the Option price, which vest immediately upon grant. Announcement • Jun 04
ME Therapeutics Holdings Inc. announced that it expects to receive CAD 0.499999 million in funding ME Therapeutics Holdings Inc. has announced a non-brokered private placement of 294,117 units at an issue price of CAD 1.70 per unit for gross proceeds of CAD 499,998.9 on June 3, 2026. Each unit consists of one common share and one non-transferrable common share purchase warrant. Each warrant will entitle the holder thereof to purchase one common share for a price of CAD 2 for a period of three years from the date of closing. All the securities issued in the offering is subject to a hold period of four months and one day from date of issuance. Completion of the Offering remains subject to, among other things, compliance with applicable securities laws and the policies of the Canadian Securities Exchange. Insider participation is expected in the Offering, although the extent and particulars have not been confirmed. The issuance of securities to insiders of the Company. Announcement • May 01
ME Therapeutics Holdings Inc. Provides Update on in Vivo CAR and Therapeutic mRNA Programs ME Therapeutics Holdings Inc. had continued to advance its in vivo chimeric antigen receptor (CAR) pipeline. The lead candidate is a dual CD19/CD22-targeted CAR that combines the recently licensed CD22 nanobody asset with a clinically tested CD19 construct. The CAR mRNAs are continuing to be optimized for expression and function in both T cells and myeloid cells. In parallel, ME Therapeutics is testing lipid nanoparticle (LNP) formulations engineered for effective in vivo mRNA delivery to human T cells and macrophages. Following optimization of the CAR mRNAs, ME Therapeutics will develop the lead CAR into specific LNP formulations for testing in humanized mouse cancer models. The CD19/CD22 dual CAR program aims to target certain forms of leukemia, lymphoma and autoimmune disease indications. Preclinical testing is also progressing for ME Therapeutics’ lead therapeutic mRNA candidate targeting the STING (Stimulator of Interferon Genes) pathway. Recent data demonstrate dose-dependent single agent efficacy of the candidate in a mouse colorectal cancer model. Two modified versions of the candidate have been optimized to enhance expression of STING in the tumour microenvironment to potentially further increase their safety and will now move forward for further testing. The STING program aims to target solid tumours such as certain forms of colorectal cancer that are currently underserved by other immuno-oncology drugs. Announcement • Feb 02
ME Therapeutics Holdings Inc., Annual General Meeting, Apr 09, 2026 ME Therapeutics Holdings Inc., Annual General Meeting, Apr 09, 2026. Announcement • Sep 28
ME Therapeutics Holdings Inc. Secures U.S. Patent for Lead Candidate and Advances Broader Therapeutic Programs ME Therapeutics Holdings Inc. announced its subsidiary, ME Therapeutics Inc., has secured a U.S. patent for its lead G-CSF antibody candidate, as it continues to advance its broader drug development and discovery programs for cancer. U.S. patent received. ME Therapeutics has received US Patent No. 12,421,308 from the United States Patent and Trademark Office (USPTO) for its G-CSF antibody candidate. The patent protects the amino acid sequence of the antibody candidate and its therapeutic use for cancer treatment in the United States. The antibody candidate, also known as H1B11-12, is a humanized biological drug formulated to target and block G-CSF, a glycoprotein cytokine known to drive immune suppression in the tumour microenvironment. The U.S. patent marks the second international patent ME Therapeutics has received for the G- CSF antibody candidate. In 2023, ME Therapeutics also received a patent from the China National Intellectual Property Administration. Other highlights: Antibody candidate cell line development: To support clinical trial regulatory meetings, ME Therapeutics is progressing cell line development to meet Good Manufacturing Practices (GMP) standards. Work at the contract research organization has identified candidate cell lines demonstrating robust antibody production and stability. Next steps will involve continued testing of the antibody characteristics prior to choosing a lead clone for the development of a GMP master cell bank. Therapeutic mRNA candidates preclinical testing: The Company's therapeutic mRNA program is advancing through preclinical testing, with the lead therapeutic mRNA candidate tested in vivo. To date, results show the lead therapeutic mRNA candidate leads to immune cell recruitment into the tumour microenvironment (TME). ME Therapeutics now intends to initiate a study to test the lead candidate in a mouse colon cancer model, both alone and in combination with an immune checkpoint inhibitor. Meanwhile, their second therapeutic mRNA candidate has demonstrated strong T cell activation in vitro. This candidate will continue to be advanced through further in vitro testing. In vivo CAR program discovery: ME Therapeutics is also progressing its in vivo CAR program through the discovery stage. This next-generation approach delivers genetic instructions directly into a patient's body to reprogram cells within the TME. The Company has confirmed in vitro activity of its tumour-targeted CARs and plans to conduct further in vitro testing before exploring in vivo testing. Expanded research team: ME Therapeutics continues to grow its research and development capabilities with the addition of two new associate research scientists. This positions the company to move its lead antibody candidate towards clinical trials as well as accelerate progress for its broader drug development and discovery program. Announcement • May 21
ME Therapeutics Holdings in Announces its Subsidiary, ME Therapeutics Inc Receiving Advisory Services and Up to $140,000 in Funding from the National Research Council of Canada Industrial Research Assistance Program ME Therapeutics Holdings In announced that its subsidiary, ME Therapeutics Inc., is receiving advisory services and up to $140,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The project will support the research and development of ME Therapeutic’s mRNA therapeutic program targeting myeloid cell biology for the treatment of cancer and inflammatory disease. “We are pleased to receive this support from NRC IRAP, which builds on advisory services and funding received in past years, to allow us to further advance preclinical studies for our mRNA therapeutic candidates that target key myeloid cell pathways,” said Salim Dhanji, CEO of ME Therapeutics. “Our team at ME Therapeutics passionately believes myeloid cell-derived mRNA therapies represent the next wave of treatments for patients with cancer and inflammatory disease who today have limited treatment options, and we are committed to bringing these potential new approaches to the clinic as soon as possible.” ME Therapeutics’s proprietary mRNA sequences have been engineered to encode for proteins that can modify the immune response in vivo in a targeted manner. Their lead mRNA therapeutic candidate is specifically designed to modulate immune cells in the tumour microenvironment and stimulate an anti-cancer immune response. Preclinical testing has already demonstrated encouraging anti-cancer activity in a mouse model of colorectal cancer. In addition, ME Therapeutics is exploring design modifications of its mRNA candidates to modulate mRNA expression in a tissue-specific manner for increased efficacy and safety. Announcement • Jan 20
ME Therapeutics Holdings Inc., Annual General Meeting, Mar 27, 2025 ME Therapeutics Holdings Inc., Annual General Meeting, Mar 27, 2025. Announcement • Jan 17
ME Therapeutics Holdings Inc. Announces First Therapeutic mRNA Candidate Shows Encouraging Anti-Cancer Efficacy in Vivo ME Therapeutics Holdings Inc. announced that its first therapeutic mRNA candidate from its strategic collaboration with NanoVation Therapeutics Inc. has demonstrated encouraging anti-cancer activity in a mouse model of colorectal cancer. The Company is planning follow-up studies to confirm the anti-cancer effect as well as to further characterize the mechanism of action of the lead mRNA candidate. Given the encouraging results, the Company has decided to expand on its therapeutic mRNA research and development program. Myeloid Enhancement (ME) Therapeutics is a preclinical stage, Vancouver based biotechnology company involved in the discovery and development of novel immuno-oncology therapeutics targeting immune suppression in cancer. The focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells to enhance anti-cancer immunity. Announcement • Oct 28
ME Therapeutics Holdings Inc. Appoints Karim Lalji as Chief Business Officer ME Therapeutics Holdings Inc. announced the appointment of Karim Lalji as Chief Business Officer. Karim Lalji, an accomplished biopharmaceutical executive, has consistently driven growth and shareholder value throughout his career. As Global Marketing Director at Merck &Co., he played a pivotal role in launching the revolutionary HIV treatment CRIXIVAN, which transformed HIV management. He also led the FOSAMAX franchise, an osteoporosis treatment that exceeded $1 billion in annual sales under his tenure. As Vice President of Business Strategy and New Product Commercialization at Sepracor Inc., Mr. Lalji spearheaded the successful commercialization of the company's pipeline including LUNESTA, driving sales from under $50 million to over $1 billion. Later, as Chief Commercial Officer at Cardiome Pharma Corp., he secured a $1 billion global licensing agreement for an anti-arrhythmia therapy-the largest licensing deal by a Canadian company at the time-and led the acquisition of Correvio International SARL, expanding the company's global footprint. Most recently, as CEO and Chairman of Microbion Pharma, Mr. Lalji raised over $60 million in capital, including $20 million in non-dilutive funding. He guided the company through multiple Phase 2 clinical trials, secured FDA Fast Track status, and obtained two Orphan Drug Designations-strategically positioning the company for future success. Mr. Lalji holds a Master's degree in Health Policy and Management from Harvard University and a BBA from Simon Fraser University. He has also served on boards, including Harvard's Beth Israel Deaconess Medical Center. Mr. Lalji has been an advisor to ME Therapeutics Inc., the operating subsidiary of the Company, since October 1, 2022, and his role as Chief Business Officer will initially be on a part time basis. Mr. Lalji is paid cash consulting fees in connection with the services he provides to the Company. Announcement • Oct 23
Me Therapeutics Holdings Inc. Provides Research and Development Update ME Therapeutics Holdings Inc. updated investors on the progress of research and development. G-CSF Antibody Candidate Update; The Company is continuing to advance lead anti-G-CSF antibody candidate, h1B11-12, towards a potential first-in-human clinical trial. The company have initiated the development of a cell line for future good manufacturing practices (GMP) production of h1B11-12 with an experienced partner organization. The company anticipates this work to be complete in the second half of 2025. Concurrently, the Company is working with its advisors to choose an appropriate patient population and trial design for its potential clinical trial to be able to conduct any potential supporting nonclinical studies that may be required. 
